Agilent Technologies is projected to report first-quarter consensus revenue of $1.81 billion and EPS of $1.37, with its current stock price of $124.40 trading significantly below the average analyst target of $169.67.
Investors are primarily focused on the recovery of the pharmaceutical and biotech end markets to see if demand for instruments can counterbalance typical seasonal softness.
The company is benefiting from replacement cycles in mass spectrometry and liquid chromatography, alongside high-growth modalities such as GLP-1 peptide support. Analysts are also monitoring the success of the 'Ignite' operational program in driving margin expansion despite macroeconomic headwinds in the broader life sciences sector.